Your privacy, your choice

We use essential cookies to make sure the site can function. We also use optional cookies for advertising, personalisation of content, usage analysis, and social media.

By accepting optional cookies, you consent to the processing of your personal data - including transfers to third parties. Some third parties are outside of the European Economic Area, with varying standards of data protection.

See our privacy policy for more information on the use of your personal data.

for further information and to change your choices.

You are viewing the site in preview mode

Skip to main content

Table 1 Challenge questions and metrics used for performance evaluation [23]

From: A community challenge to predict clinical outcomes after immune checkpoint blockade in non-small cell lung cancer

Sub-challenge

Challenge Question

BM

Primary Metrica for Performance Evaluation

PFS

(Sub-challenge 1)

PFS/OS sub-challenges: Predict response to nivolumab, in terms of PFS/OS, via an immune checkpoint-specific model using clinical, demographic, and gene expression data

PFS/OS Harrel’s C-index

DSS BM of PFS/OS between the nivolumab and chemotherapy arms

OS

(Sub-challenge 2)

BOR

(Sub-challenge 3)

BOR sub-challenge: Predict which patients will not respond and have a BOR of PD

ROC-AUC

DSS BM of BOR between the nivolumab and chemotherapy arms

  1. AUC area under the curve, BOR best overall response, C-index concordance index, DSS BM difference in squared scaled basal metrics, OS overall survival, PD progressive disease, PFS progression-free survival, ROC receiver operating characteristic
  2. aThe computing of the primary metric from the BM is shown in Additional file 1: Fig. S1
Back to article page

Journal of Translational Medicine

ISSN: 1479-5876

Contact us